November 26, 2024 Clinical Research/Diagn. M&A, Partnerships

Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies

Acquisition supports Roche’s Pharma Strategy and allows for a range of potentially first and best-in-class therapies across oncology, immunology, and neurology, uniquely positioning Roche in the new field of donor-derived off-the-shelf cell therapies Roche to acquire Poseida Therapeutics for US $9.00 per share in cash at closing, representing a total equity value of approximately US... Read more

November 26, 2024 Bio/Pharma/CRO

Roche reports update on Phase III SKYSCRAPER-01 study results

Basel, 26 November 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) reports an update on the phase III SKYSCRAPER-01 study, evaluating tiragolumab combined with Tecentriq® (atezolizumab) compared to Tecentriq alone for patients with PD-L1-high, locally advanced or metastatic non-small cell lung cancer (NSCLC).  SKYSCRAPER-01 is a global phase III, randomised, double-blind study evaluating tiragolumab plus... Read more

November 5, 2024 Acad, Gov/Utilities PAI Top-10 Product Launch

Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024

Basel, 05 November 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held 7-10 December 2024 in San Diego, US. The data underscore Roche’s commitment to advance patient outcomes in... Read more

October 31, 2024 Clinical Research/Diagn. Product Launch

Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease

New data highlight the potential of the Roche Elecsys® Amyloid Plasma Panel and Elecsys ptau181 for ruling out Alzheimer’s disease related amyloid pathology with very good accuracy. In the largest worldwide clinical trial of its kind, the blood-based test showed very good accuracy in ruling out Alzheimer’s pathology in those being investigated for the disease,... Read more

October 31, 2024 Bio/Pharma/CRO PAI Top-10 Product Launch

New England Journal of Medicine publishes landmark phase III results for Roche’s Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer

ItovebiTM (inavolisib)-based regimen demonstrated a statistically significant and clinically meaningful benefit, reducing the risk of disease worsening or death by 57% compared with palbociclib and fulvestrant alone in the INAVO120 study1 The U.S. FDA recently approved the Itovebi-based regimen as a first-line treatment for people with HR-positive, HER2-negative breast cancer with a PIK3CA mutation, one... Read more

October 23, 2024 PAI Top-10 PR/Corporate

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine months

Group sales grew by 6%1 at constant exchange rates (CER) (2% in CHF) in the first nine months, driven by the high demand for both our medicines and diagnostics; excluding COVID-19-related products, sales increased by 8% In the third quarter, Group sales rose by 9% (6% in CHF), as they did in the second quarter... Read more

January 16, 2024 Licensing, IP, and Legal

European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types

Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians1-5 Tecentriq SC reduces treatment time by approximately 80%, compared with standard IV infusion6 Roche is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as... Read more

December 29, 2023 Clinical Research/Diagn. Licensing, IP, and Legal M&A, Partnerships

Roche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform

The transformative point of care solution will complement Roche’s centralised diagnostics portfolio across Clinical Chemistry, Immunochemistry, Coagulation and Molecular, and across multiple disease areas LumiraDx’s technology integrates multiple Point of Care tests on a simple to use single instrument and brings more affordable and accessible testing to patients worldwide Under the terms of the agreement,... Read more

December 19, 2023 Acad, Gov/Utilities Bio/Pharma/CRO

FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results

If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure Interim analysis results from first-of-its-kind phase III OUtMATCH study showed Xolair significantly increased the amount of peanut, milk, egg and cashew it took to cause an allergic reaction 17 million people in the U.S. have confirmed... Read more

December 15, 2023 Environ, Ag./Food & Bev PR/Corporate

Roche named among top three most sustainable healthcare companies in the Dow Jones Sustainability Indices

The ranking acknowledges Roche’s commitment to sustainability as an integral part of its business strategy Roche performed particularly well in innovation management, access to healthcare, greenhouse gas emissions, water management, resource efficiency and circularity, labour practice indicators and human rights This marks the 15th consecutive year that Roche has maintained its leading ranking Basel, 15... Read more